-
EP4093384
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4093384
| EP4093384 - NOVEL CELL METABOLISM MODULATING COMPOUNDS AND USES THEREOF [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 28.10.2022 Database last updated on 19.10.2024 | |
| Former | The international publication has been made Status updated on 30.07.2021 | Most recent event Tooltip | 10.09.2024 | Supplementary search report | published on 09.10.2024 [2024/41] | Applicant(s) | For all designated states Crescenta Biosciences 1075 Morris Avenue Stem Building Suite 403 Union, NJ 07083 / US | [2022/48] | Inventor(s) | 01 /
KOYUNCU, Emre 172 Willowbend Irvine, California 92612 / US | 02 /
KIM, Hahn 808 Barclay Blvd. PRINCETON, New Jersey 08540 / US | [2022/48] | Representative(s) | Biggi, Cristina Bugnion S.p.A. Viale Lancetti 17 20158 Milano / IT | [2022/48] | Application number, filing date | 21744382.9 | 20.01.2021 | [2022/48] | WO2021US14250 | Priority number, date | US202062963508P | 20.01.2020 Original published format: US 202062963508 P | [2022/48] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2021150645 | Date: | 29.07.2021 | Language: | EN | [2021/30] | Type: | A1 Application with search report | No.: | EP4093384 | Date: | 30.11.2022 | Language: | EN | The application published by WIPO in one of the EPO official languages on 29.07.2021 takes the place of the publication of the European patent application. | [2022/48] | Search report(s) | International search report - published on: | US | 29.07.2021 | (Supplementary) European search report - dispatched on: | EP | 09.09.2024 | Classification | IPC: | A61K31/05, A61K31/352, A61K31/417, C07D401/08 | [2024/22] | CPC: |
A61K31/47 (EP,KR);
C07D215/38 (EP,KR,US);
A61K31/4709 (KR);
A61K31/497 (EP);
A61K31/498 (EP);
A61K31/506 (EP);
A61K31/5377 (KR);
A61P1/16 (KR);
A61P11/06 (KR);
A61P25/28 (KR);
A61P3/04 (KR);
A61P3/10 (KR);
A61P35/00 (KR);
A61P9/10 (KR);
C07D215/14 (EP);
C07D215/227 (EP);
C07D235/30 (US);
C07D401/04 (EP,KR,US);
C07D401/08 (EP,US);
C07D401/12 (EP,KR,US);
C07D401/14 (KR,US);
C07D413/04 (EP,US);
C07D413/08 (EP);
C07D417/04 (US);
| C-Set: |
A61K31/47, A61K2300/00 (EP);
A61K31/497, A61K2300/00 (EP);
A61K31/498, A61K2300/00 (EP);
A61K31/506, A61K2300/00 (EP) |
| Former IPC [2022/48] | A61K31/05, A61K31/352, A61K31/417 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2022/48] | Title | German: | NEUARTIGE ZELLMETABOLISMUSMODULIERENDE VERBINDUNGEN UND DEREN VERWENDUNGEN | [2022/48] | English: | NOVEL CELL METABOLISM MODULATING COMPOUNDS AND USES THEREOF | [2022/48] | French: | NOUVEAUX COMPOSÉS MODULATEURS DU MÉTABOLISME CELLULAIRE ET LEURS UTILISATIONS | [2022/48] | Entry into regional phase | 19.08.2022 | National basic fee paid | 19.08.2022 | Search fee paid | 19.08.2022 | Designation fee(s) paid | 19.08.2022 | Examination fee paid | Examination procedure | 19.08.2022 | Amendment by applicant (claims and/or description) | 19.08.2022 | Examination requested [2022/48] | Fees paid | Renewal fee | 19.08.2022 | Renewal fee patent year 03 | 17.01.2024 | Renewal fee patent year 04 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [A]WO2004099159 (INST FOR PHARM DISCOVERY INC [US], et al); | [E]WO2022010948 (CRESCENTA BIOSCIENCES [US]); | International search | [A]US5541196 (FOURNET ALAIN [FR], et al); |